Accès ouvert
2025
article
OpenAlex
Arvind Bakthavatsalam, Billanna Hwang, Michael S. Mulligan
Background Lung transplantation (LTx) is a key treatment for end-stage pulmonary disease, yet survival lags other organ transplants. Prior major cardiothoracic (CT) may negatively affect short- and long-term outcomes but is not a contraindication to LTx. This study investigates the effect of …
us
(code pays fourni par la source)
2024
article
OpenAlex
Arvind Bakthavatsalam, Billanna Hwang, Michael S. Mulligan
us
(code pays fourni par la source)
2024
article
OpenAlex
Arvind Bakthavatsalam, Billanna Hwang, Aaron M. Cheng, Noah C. Ircink et autres
us
(code pays fourni par la source)
2024
article
OpenAlex
Arvind Bakthavatsalam, Lena Sibulesky, Nicolae Leca, Stephen C. Rayhill et autres
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Arvind Bakthavatsalam, Billanna Hwang, Aaron M. Cheng, Noah C. Ircink et autres
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
K. Olsson, Kevin Mani, Anne Burdess, Suzannah Patterson et autres
Importance: Endovascular treatment is not recommended for aortic pathologies in patients with connective tissue diseases (CTDs) other than in redo operations and as bridging procedures in emergencies. However, recent developments in endovascular technology may challenge this dogma. Objective: To assess the midterm …
se, us, de, it, gb, fr, cn, hk, be, nz, dk
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
Zachary R. Stephen, Christopher J. Dayringer, Josh J. Lim, Richard A. Revia et autres
Surface functionalization of theranostic nanoparticles (NPs) typically relies on lengthy, aqueous postsynthesis labeling chemistries that have limited ability to fine-tune surface properties and can lead to NP heterogeneity. The need for a rapid, simple synthesis approach that can provide great control over …
us
(code pays fourni par la source)
Accès ouvert
2015
article
OpenAlex
Kui Wang, Forrest M. Kievit, Jonathan G. Sham, Mike Jeon et autres
Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Small interfering RNA (siRNA) holds promise as a new class of therapeutics for HCC, as it can achieve sequence-specific gene knockdown with low cytotoxicity. However, the main challenge in the clinical application …
us
(code pays fourni par la source)